Radiation and High-Dose Metronidazole in Supratentorial Glioblastomas
| Autor: | C.G. Fryer, J D Chapman, Urtasun Rc, B Mielke, Pierre R. Band, M L Feldstein |
|---|---|
| Rok vydání: | 1976 |
| Předmět: |
Adult
Oncology Radiation-Sensitizing Agents medicine.medical_specialty Radiosensitizer Time Factors Remission Spontaneous Administration Oral law.invention Randomized controlled trial In vivo law Metronidazole Radioresistance Internal medicine medicine Humans Cobalt Radioisotopes Survival analysis Aged Brain Neoplasms business.industry General Medicine Middle Aged Radiation effect Clinical trial Evaluation Studies as Topic Glioblastoma Nuclear medicine business medicine.drug |
| Zdroj: | New England Journal of Medicine. 294:1364-1367 |
| ISSN: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejm197606172942503 |
| Popis: | We used "high-dose" metronidazole, an "in vitro" and "in vivo" specific radiosensitizer of hypoxic cells, in a controlled trial to evaluate possible enhancement of radiation effect in patients with supratentorial glioblastomas. Thirty-six patients were stratified according to functional level and randomly allocated within two weeks of operation to one of two therapeutic groups: Group 1, radiation alone; and Group 2, radiation as in Group 1 but with high-dose metronidazole. We examined survival with the Kaplan-Meier probability plot and non-parametric tests. Patients in Group 2 had a 4 1/2-month delay between relapse and subsequent death (P = 0.02). This shift of the survival curves suggests a delay in the time of tumor regrowth consistent with the ability of metronidazole to make the hypoxic tumor cells less radioresistant. Nitroimidazole derivatives may be useful radiosensitizers in human solid tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|